General healthcare issues related to generic and biosimilar industries.
2025 · 3rd Quarter (July 1 - Sep 30)
FRESENIUS KABI USA LLC
Filed by FEROX STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- FEROX STRATEGIES
- Client
- FRESENIUS KABI USA LLC
- Filing UUID
- cab1a202-d72c-44fb-9dfb-bbdf0b3948c7
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
General patent issues related to generic and biosimilar industries.
General issues related to trade.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.